SCHEMBL20132914

SCHEMBL20132914

Cn1c2ccncc2c2ccc(-c3ccc(OC4CCC4)nc3)cc21

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.41
TDO2 P48775 3/20 0.41
ATM Q13315 5/20 0.39
ATR Q13535 1/20 0.39
SYK P43405 1/20 0.38
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MAPT P10636 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
KCNH2 Q12809 1/20 0.36
MTOR P42345 2/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CD O00329 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29773844 0.91 TDO2 (0.48) HRH3TDO2ATMATRSYK
SCHEMBL20133115 0.91 TDO2 (0.48) HRH3TDO2ATMATRSYK
SCHEMBL29547763 0.91 TDO2 (0.48) HRH3TDO2ATMATRSYK
SCHEMBL29547511 0.88 TDO2 (0.38) HRH3TDO2ATMATRSYK
SCHEMBL20129037 0.88 TDO2 (0.38) HRH3TDO2ATMATRSYK
SCHEMBL20129152 0.87 TDO2 (0.38) HRH3TDO2ATMATRNPC1
SCHEMBL29547432 0.87 TDO2 (0.38) HRH3TDO2ATMATRNPC1
SCHEMBL27098621 0.87 MKNK1 (0.43) HRH3TDO2ATMATRNPC1
SCHEMBL20120825 0.87 TDO2 (0.38) HRH3TDO2ATMATRNPC1
SCHEMBL20120826 0.87 TDO2 (0.38) HRH3TDO2ATMATRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 WO disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN HRH3 3443/4885TDO2 3503/4885ATM 711/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 HRH3 3565/4885TDO2 3395/4885ATM 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.